“I remember the physicians had such a huge impact on my family. In the worst times of your life, it’s the physicians who are there, and they have the potential to make such a huge difference.”
When Jackson was five years old, her younger sister was diagnosed with acute lymphoblastic leukemia. It was a painful and terrifying prognosis, which shaped Jackson’s earliest memories, and changed her perspective on medicine forever.
At an age where most children are still barely beginning to grasp the concept of life in the world, many of Jackson’s formative years were spent by her sister’s hospital bedside.
“I remember the physicians had such a huge impact on my family. In the worst times of your life, it’s the physicians who are there, and they have the potential to make such a huge difference.”
Although her parents both have jobs in the business sector, after her sister’s diagnosis they became rapidly involved in her medical care, frantic to understand the cause as well as the treatment plans that were available.
Always a curious child, Jackson wanted to understand everything that was happening as well.
“I always asked the doctors way too many questions,”
Jackson laughs. “It’s kind of funny to remember the doctors’ explanations to me then, knowing what I know now.”
The discovery of the targeted therapy drug Gleevec by Oregon Health and Science University (OHSU) scientist Brian Druker occurred at this time, which revolutionized treatment for chronic myeloid leukemia. As a frequent visitor to the Doernbecher Children’s Hospital at OHSU, Jackson was able to witness some of the first FDA-approved treatments with the new drug, and saw the incredible impact it had on other children that she had become friends with.
“It really drove home that it wasn’t just the physicians and the treatment that were helping my sister and other patients – it was the research that was behind all of it,” Jackson explains.
This discovery helped solidify her ultimate goal of being a physician scientist, which would allow her to perform research while also treating patients and observing the disease up close.
“I think it’s very unique that my situation turned out to have such a positive impact on my life,” explains Jackson. “My sister jokes now that she was the launchpad for my career.”
Originally from Lake Oswego, Oregon, Jackson was introduced to research in high school as an intern at OHSU. Although she was too young to have her own research project, it gave her a taste for working in a laboratory and a hunger for more.
“The big reason why I came to OSU, and why I really love it, is because of the research opportunities,” she explains.
Jackson first met Freitag early in her freshman year at a faculty mixer hosted by the Honors College, and grew interested in his research on epigenetic silencing.
That winter, she applied for URSA Engage, an OSU program intended to establish mentoring relationships for first- and second-year students. Jackson was dismayed to hear that she had not been accepted into the program. Fortunately, Freitag was able to see her potential, and made space to accommodate her in his lab for her Honor’s thesis project.
“The big reason that I came to OSU, and why I really love it, is because of the research opportunities,” she explains.
Now, it feels good to have her scientific abilities recognized on a national level.